PFE Today - Jul 13: Price Target Cuts Hit Hard

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

PFE Today - Jul 13: Price Target Cuts Hit Hard

無料で聴く

ポッドキャストの詳細を見る

Hey there! It's Joey, your friendly investor buddy, breaking down what went down today with Pfizer. So, PFE had a bit of a green day, up about 1.82%. Not too shabby, right?

But hold on, it wasn’t all sunshine and rainbows. The stock kinda had a rough ride earlier in the week. Today’s uptick was like a small bounce back after some recent price target cuts from analysts. Guggenheim lowered its target to $35, and BMO Capital followed suit, dropping theirs to $30. That’s never a fun thing to hear as a shareholder. People were probably feeling a bit jittery about it.

Now, let’s talk about the why behind today’s action. Despite those price cuts, Pfizer scored a big win with FDA approval for its Lyme disease vaccine, showing a promising 70% efficacy. That’s incredible news, but it seems like Wall Street wasn’t super excited about it. The reaction was kinda muted, like when you tell your friends about a cool new game and they’re just like, “Yeah, cool.” It’s a bummer when good news doesn’t translate to excitement on the stock side, right?

And get this—there's a lot going on in the healthcare space right now. While Pfizer's vaccine news is solid, the market's still buzzing about other big players making moves, like Novo Nordisk launching a subscription model for Wegovy. Everyone's trying to figure out how these shifts impact the whole scene.

So, yeah, that’s the lowdown on Pfizer today. Always a mix of wins and losses in the stock game. Just remember, this is all info for you to chew on, not financial advice or anything. Keep your head up, and I’ll catch you later!

まだレビューはありません